Recent studies of sterile filtration of a Live Attenuated Virus (LAV) demonstrated that the Sartobran P sterile filter provided 80% yield of a LAV that was 100 - 400 nm in size, raising questions about the effectiveness of this filter in retaining the standard challenge bacterium, Brevundimonas diminuta. This study evaluated the retention of B. diminuta by the Sartobran P over a range of conditions appropriate for LAV filtration. The B. diminuta were characterized by dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), and scanning electron microscopy. The Sartobran P showed complete retention of B. diminuta under all conditions, even in the presence of additives like sucrose, surfactants, and high salt that have previously been hypothesized to increase the risk of bacterial breakthrough. The size of B. diminuta decreased when incubated in the nutrient poor media required by the ASTM challenge test. The addition of sucrose caused a further reduction in size as measured by NTA, although this was due to an increase in cell motility. There was no evidence of bacterial breakthrough at high loadings of either the LAV or B. diminuta, further demonstrating the effectiveness of the Sartobran P for sterile filtration of large viral vaccines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.xphs.2022.03.022 | DOI Listing |
J Pharm Sci
July 2022
Department of Chemical Engineering, The Pennsylvania State University, USA. Electronic address:
Recent studies of sterile filtration of a Live Attenuated Virus (LAV) demonstrated that the Sartobran P sterile filter provided 80% yield of a LAV that was 100 - 400 nm in size, raising questions about the effectiveness of this filter in retaining the standard challenge bacterium, Brevundimonas diminuta. This study evaluated the retention of B. diminuta by the Sartobran P over a range of conditions appropriate for LAV filtration.
View Article and Find Full Text PDFBiotechnol Bioeng
January 2021
Department of Chemical Engineering, The Pennsylvania State University, State College, Pennsylvania, USA.
There is growing interest in the development of new vaccines based on live-attenuated viruses (LAVs) and virus-like particles. The large size of these vaccines, typically 100-400 nm, significantly complicates the use of sterile filtration. The objectives of this study are to examine the performance of several commercial sterile filters for filtration of a cytomegalovirus vaccine candidate (referred to as the LAV) and to develop and evaluate the use of a model nanoparticle suspension to perform a more quantitative assessment.
View Article and Find Full Text PDFVaccine
June 2007
Gene Transfer and Somatic Cell Engineering Facility, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
The use of plasmid DNA as vaccines for the treatment of cancer and infectious diseases is on the rise. In order to facilitate the manufacture of clinical-grade plasmid DNA for Phase I clinical trials, we developed a process whereby >200 mg plasmid could be produced in a single production run under Good Manufacturing Practices. A dedicated cleanroom (Class 10,000 with Class 100 biosafety cabinet) is utilized for production of the bacterial cell bank, fermentation, harvest/lysis of the biomass, and downstream purification.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!